针对卵巢癌的叶酸受体α的治疗策略
Jia Mai1, Limei Wu1,2, Ling Yang1
1Department of Laboratory Medicine, Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Center of Growth, Metabolism and Aging, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
表皮卵巢癌 (EOC) 是一种致命的妇科癌症. 本综述涵盖了针对叶酸受体α (FRα) 的疗法,包括用于EOC治疗的已批准的抗体-药物结合物mirvetuximab soravtansine.
科学领域:
- 妇科瘤学 妇科瘤学
- 翻译癌症研究 翻译癌症研究
- 药理学 药理学 是一个学科.
背景情况:
- 由于治疗选择有限,上皮卵巢癌 (EOC) 构成了重大的临床挑战.
- 叶酸受体α (FRα),在EOC中高度表达,是一个有前途的治疗点.
- 目前的研究探讨了用于EOC治疗的各种FRα向策略.
研究的目的:
- 审查FRα的功能和基于FRα的EOC治疗药物的临床疗效.
- 要突出FRα向剂的进展,包括抗体与药物联合体 (ADCs).
- 讨论第一个FDA批准的FRα向ADC,Mirvetuximab soravtansine,用于抗卵巢癌.
主要方法:
- 关于FRα及其向疗法的基础和翻译研究的文献综述.
- 对基于FRα的卵巢癌治疗方法的临床试验数据的分析.
- 已批准的FRα向剂及其作用机制的概述.
主要成果:
- 在EOC中,FRα是经过验证的标,其多种治疗方式显示出前景.
- 米尔韦图西马布 (Mirvetuximab soravtansine,简称MIRV) 是第一个被批准用于抗EOC的FRα向ADC.
- 目前正在研究各种基于FRα的疗法,包括ADC,单克隆抗体和合物.
结论:
- 针对FRα的疗法代表了EOC治疗的重大进步,特别是在耐药性疾病中.
- 米尔韦图西马布 (Mirvetuximab soravtansine) 为患有抗性卵巢癌的患者提供了一种新的治疗选择.
- 进一步研究FRα向剂和相关不良事件的管理,如眼部毒性,是有必要的.
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Drugs that Stabilize Microtubules
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists


